Trial watch: Naked and vectored DNA-based anticancer vaccines.

April 2, 2015
Source: Oncoimmunology. 2015 Apr 2;4(5):e1026531. eCollection 2015 May.

Authors: N. Bloy, A. Buqué, F. Aranda, F. Castoldi, A. Eggermont, I. Cremer, C. Sautès-Fridman, J. Fučiková, J. Galon, R. Špíšek, E. Tartour, L. Zitvogel, G. Kroemer, L. Galluzzi


One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is to drive the synthesis of TAAs in the context of an immunostimulatory milieu, resulting in the (re-)elicitation of a tumor-targeting immune response. In spite of encouraging preclinical results, the clinical efficacy of DNA-based vaccines employed as standalone immunotherapeutic interventions in cancer patients appears to be limited. Thus, efforts are currently being devoted to the development of combinatorial regimens that allow DNA-based anticancer vaccines to elicit clinically relevant immune responses. Here, we discuss recent advances in the preclinical and clinical development of this therapeutic paradigm.